Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer

DISEASE CHARACTERISTICS:

* One of the following diagnoses:

  * Histologically confirmed good-risk acute myeloid leukemia (AML) in first remission with an HLA-compatible related donor

    * Ineligible for unrelated bone marrow transplantation unless failed first-line induction chemotherapy or have molecular evidence of disease at time of transplantation
  * Histologically confirmed high-risk AML in first remission

    * High risk defined by cytogenetics, biphenotypic and undifferentiated leukemia phenotype, secondary AML, or AML after myelodysplastic syndromes (MDS)
    * Eligible for related or unrelated donor transplantation
  * Histologically confirmed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) in first remission with high risk for relapse or in second or third remission

    * High risk for relapse defined by hypodiploidy, pseudodiploidy with translocations t(9;22) or infant t(4;11), or failure to achieve remission after four weeks of induction therapy
    * Eligible for related or unrelated donor transplantation
  * Histologically confirmed chronic myelogenous leukemia (CML) in at least first chronic phase or acceleration with an HLA-compatible related donor
  * Histologically confirmed CML in first chronic phase if failed conventional therapy or in at least second chronic phase or acceleration with an HLA-compatible unrelated donor
  * Histologically confirmed non-Hodgkin's lymphoma beyond first complete remission or primary induction failure and tumors that are chemosensitive defined as at least 50% reduction in mass size

    * Eligible for related or unrelated donor transplantation
  * Histologically confirmed MDS with intermediate or high-risk disease defined by International Prognostic Scoring System and paroxysmal nocturnal hematuria

    * Eligible for related or unrelated donor transplantation
* Treatment-related MDS or leukemia allowed if primary malignancy (e.g., neuroblastoma or Ewing's sarcoma) at low risk of recurrence
* No AML, ALL, or LL in relapse or greater than third remission
* No CML in blast crisis defined as more than 30% blasts plus promyelocytes
* No active CNS involvement
* History of leukemia cutis allowed
* HLA compatible donor available

  * 5/6 or 6/6 HLA antigen matched related or unrelated

PATIENT CHARACTERISTICS:

Age:

* 18 and under

Performance status:

* Karnofsky 70-100% OR
* Lansky 50-100%

Life expectancy:

* Not specified

Hematopoietic:

* See Disease Characteristics

Hepatic:

* Bilirubin no greater than 2.5 times upper limit of normal (ULN)
* AST no greater than 3 times ULN (unless liver involvement is present)

Renal:

* Creatinine normal OR
* Creatinine clearance greater than 60 mL/min

Cardiovascular:

* LVEF at least 50% at rest (if less than 50% at rest, must increase with exercise)

Pulmonary:

* Asymptomatic with no prior risk features OR
* DLCO greater than 40% predicted (corrected for hemoglobin) if symptomatic

Other:

* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV I/II negative
* No uncontrolled viral, bacterial, or fungal infection
* No known hypersensitivity to bovine proteins

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* See Disease Characterisitics

Chemotherapy:

* See Disease Characteristics

Endocrine therapy:

* Not specified

Radiotherapy:

* No prior radiotherapy that would preclude total body irradiation dose

Surgery:

* Not specified